Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares RepurchasedShort-Term Debt repayments
Ratios

United Therapeutics (UTHR) Receivables - Net (2016 - 2025)

United Therapeutics' Receivables - Net history spans 17 years, with the latest figure at $350.2 million for Q4 2025.

  • For Q4 2025, Receivables - Net rose 25.38% year-over-year to $350.2 million; the TTM value through Dec 2025 reached $350.2 million, up 25.38%, while the annual FY2025 figure was $350.2 million, 25.38% up from the prior year.
  • Receivables - Net for Q4 2025 was $350.2 million at United Therapeutics, up from $297.7 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $379.3 million in Q2 2025 and bottomed at $134.5 million in Q1 2023.
  • The 5-year median for Receivables - Net is $265.6 million (2023), against an average of $251.8 million.
  • The largest annual shift saw Receivables - Net dropped 21.11% in 2023 before it skyrocketed 128.48% in 2024.
  • A 5-year view of Receivables - Net shows it stood at $198.7 million in 2021, then rose by 10.92% to $220.4 million in 2022, then increased by 26.54% to $278.9 million in 2023, then rose by 0.14% to $279.3 million in 2024, then grew by 25.38% to $350.2 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Receivables - Net are $350.2 million (Q4 2025), $297.7 million (Q3 2025), and $379.3 million (Q2 2025).